Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
Recent Articles
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
